Social Media Discussions on Meds Give Rise to “Patient Influencers”
To better understand the new phenomenon of “patient influencers”, the authors conducted interviews with individuals who routinely offer advice on health topics on social media.
Diagnosis & Disease Information
APA Releases New Practice Guideline on Evaluating and Managing Eating Disorders
A new practice guideline for the treatment of patients with eating disorders.
Updated Guidelines on Optimal Antibiotic Dosing for Patients With Obesity
Researchers evaluated clinical trial data and drug databases to provide updated recommendations on antimicrobial dosing for patients with obesity.
Tirzepatide Superior to Placebo in Weight Loss Study
The SURMOUNT-1 trial evaluated tirzepatide as an adjunct to a reduced-calorie diet and increased physical activity in adults without type 2 diabetes who have obesity or are overweight.
Obesity Organizations Release Consensus Statement
Six organizations that focus on the diagnosis and treatment of obesity have released a consensus statement to reduce barriers to care.
Fecal Microbiota Transplantation Does Not Alter Weight Loss in Bariatric Surgery
Researchers sought to determine whether fecal microbiota transplantation from a lean donor contributes to an improvement in bariatric surgery outcomes.
We Have Better Obesity Medications, but Access Is Lagging
Obesity experts discuss the cost of newer obesity medications (eg, GLP-1 agonists) and access issues, including Ozempic shortages.
Weight Loss Supplement Contains Potentially Dangerous Ingredient for Some
Sibutramine is a controlled substance that was voluntarily withdrawn from the market in October 2010.
Palpitations, Fatigue, Angina More Likely After COVID-19 vs Other Viral Infections
Researchers conducted a study to assess the long-term effects of COVID-19 infection in comparison with other common respiratory viral infections.
Wegovy Gains Approval for Treating Obesity in Adolescents
Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.
- Loading...
Loading...
Loading... 
Loading...